Amgen: Repatha Cuts Risk Of First Major Cardiovascular Events By 31% In High-risk Patients Without Known Significant Atherosclerosis
Amgen's Repatha reduced the risk of first major cardiovascular events by 31% in high-risk patients without known significant atherosclerosis. The results were presented at the American College of Cardiology's 75th Annual Scientific Session and published in the Journal of the American Medical Association.
Amgen announced that Repatha, when added to statins or other treatments, reduced the risk of first major adverse cardiovascular events in high-risk primary prevention patients with diabetes. The study followed 3,655 patients for a median of 4.8 years. Repatha reduced the risk of coronary heart disease death, myocardial infarction, or ischemic stroke by 31%. The median achieved LDL-C was 44 mg/dL at 96 weeks. Repatha demonstrated consistent benefit across secondary endpoints, including heart attack, ischemic stroke, and revascularization. The results reinforce the importance of earlier, more intensive lowering of LDL-C to prevent cardiovascular events.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.